Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
$BBIO Completes Enrollment of FORTIFY, Phase 3 Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9. Study exceeded target enrollment. Topline data readout from the interim analysis expected in 2025
$ADXN (+16.1% pre) Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update - GN https://t.co/k51ZdBsyIQ
$ALT Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in MASH. Topline efficacy data expected in Q2.
Addex Therapeutics has disclosed its financial results for the first half and second quarter of 2024, along with a corporate update, reporting a 16.1% pre-market increase in stock price ($ADXN).